Dct-rtTA/+; tet-HA-GNAQQ209L/+; p16p19KO
|
5- to 6-week-old mice; doxycycline in food |
>50% of mice developed cutaneous melanoma; no report of lesions in the uveal tract |
Feng et al. (2014) (J. Silvio Gutkind) |
Rosa26-floxed stop-GNAQQ209L/+; Mitf-cre/+ |
Embryonic (E15.5) activation by constitutive Cre driver |
Skin hyperpigmentation overt uveal melanoma and occasional dermal melanoma at 3 months in 15/15 mice; melanocytic neoplasia of the leptomeninges, harderian gland, cochlea, and vestibular system; putative metastases in the lungs at 3 months in 18/19 mice |
Huang et al. (2015) (Catherine Van Raamsdonk) |
Rosa26-floxed stop-GNAQQ209L/+; Tyrosinase-creER/+ |
8-week-old mice; daily IP injection of tamoxifen and tail dip in 4-HT for 5 days |
Skin hyperpigmentation; melanocytic hyperplasia of the uveal tract (but not overt melanoma) in 3/3 mice |
|
R26-LSL-GNA11Q209L/+; Tyrosinase-creERT2/+ |
4-week-old mice; single IP injection of tamoxifen |
Skin hyperpigmentation; overt uveal and dermal melanoma at 6 months in 50% of mice; melanocytic neoplasia of the leptomeninges, third ventricle, harderian gland, and heart; putative metastases in axillary lymph nodes and lungs at 3–6 months in 100% of mice |
Moore et al. (2018) (Yu Chen) |
R26-LSL-GNA11Q209L/+; BAP1lox/lox; Tyrosinase-creERT2/+ |
Compared to above: increased dermal melanoma burden and proliferative index, no change in number or size of uveal melanoma tumors or lung lesions |
|
AAV5-CMV-Cre or AAV5-Trp2-GFPCre; Lats1f/f; Lats2f/f
|
2- to 4-month-old mice; suprachoroidal injection of AAV |
Eye bulging at 2 months and uveal melanoma formation at 6 months in 12/14 and 8/10 mice, respectively |
Li et al. (2019) (Junhao Mao) |
AAV5-Trp2-GFPCre; Lats1f/f; Lats2f/f; LSL-KrasG12D
|
Compared to above: larger uveal melanoma tumors in 7/7 mice and reduced survival (<4 months) |
|